WHO says it is in talks with China's BGI on test kit after Swedish complaint


GENEVA, Aug 27 (Reuters) - The World Health Organization said on Thursday it was looking into whether "observed irregularities" in a COVID-19 PCR swab test made by China's BGI Biotechnology (Wuhan) Co, Ltd were linked to how it was used in Sweden.

The WHO said it had asked the maker for a "root cause analysis".

China's BGI Genomics 300676.SZ said on Wednesday its diagnostic coronavirus testing kit has "relatively high accuracy", a day after Sweden said about 3,700 people received false positive results due to a fault in the company's product.

The WHO, which has approved the tests for emergency use, said in reply to a Reuters query: "WHO was notified and has activated the complaint procedure for in vitro diagnostics ... to gauge if the observed irregularities were due to the way the test was used.

"Specifically, WHO has contacted the manufacturer and requested a root cause analysis... We are continuing the work with BGI to determine if further action is required," it said.

(Reporting by Stephanie Nebehay in Geneva, Roxanne Liu in Beijing and Miyoung Kim in Seoul; writing by Stephanie Nebehay; ; editing by John Stonestreet)

((Stephanie.Nebehay@thomsonreuters.com; +41 58 306 2161; Reuters Messaging: stephanie.nebehay.thomsonreuters.com@reuters.net; twitter @StephNebehay))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.